AstraZeneca Tops Q1 EPS by $1.06
- ByInvesting.com-
AstraZeneca (NASDAQ:AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate...
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
AstraZeneca (NASDAQ:AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate...
Investing.com - AstraZeneca (NASDAQ:AZN) ADR reported on Friday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca ADR...
Biopharmaceutical major AstraZeneca plc (NASDAQ: AZN) recently revealed that it has signed a Master Collaboration Agreement with a molecular diagnostics company, Amoy Diagnostics...
Fed's expected aggressive tightening to contain soaring inflation, has many worrying about a possible recession.Three companies to protect your portfolio due to strong...
The stocks of the vaccine producers have gained a lot during 2021 due to the wide vaccination campaign around the world. Still, the COVID-19 pandemic is still not over as the virus...
It’s a pretty flat though mildly positive start to trade in Europe again after a decent handover from Asia, whilst Wall Street again registered fresh all-time highs. The S&P 500...
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Sell | Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 5,606.00 | 5,628.00 | 5,532.00 | -104.0 | -1.82% | 199.92K | London | |||
| 7.90 | 7.90 | 6.56 | +1.50 | +25.00% | 11.84M | London | |||
| 125.00 | 125.00 | 125.00 | -2.50 | -1.96% | 51.67K | London | |||
| 12.25 | 12.25 | 12.25 | 0.00 | 0.00% | 127.78K | London | |||
| 36.30 | 37.10 | 36.15 | +0.20 | +0.55% | 2.79K | London | |||
| 0.075 | 0.076 | 0.051 | 0.000 | 0.00% | 0.00 | London | |||
| 100.75 | 103.00 | 100.00 | -4.50 | -4.31% | 65.10K | London | |||
| 224.00 | 224.00 | 220.00 | +3.00 | +1.36% | 99.37K | London | |||
| 340.00 | 340.00 | 340.00 | +3.50 | +1.04% | 214.29K | London | |||
| 79.00 | 79.00 | 75.00 | +4.00 | +5.33% | 1.35M | London | |||
| 223.50 | 224.80 | 218.60 | +4.40 | +2.01% | 14.57M | London | |||
| 2,218.00 | 2,220.00 | 2,177.00 | +25.0 | +1.14% | 535.93K | London | |||
| 456.10 | 459.70 | 424.00 | +30.90 | +7.27% | 4.60M | London | |||
| 311.50 | 313.50 | 303.50 | +5.00 | +1.63% | 232.69K | London | |||
| 6.51 | 7.00 | 6.20 | -0.17 | -2.55% | 3.03M | London |